Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-L03 (Pioglitazone) in Type 2 Diabetes With Insufficient Control on Metformin and Empagliflozin
NCT06571591Phase 3Completed
- Sponsor
- Celltrion
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
A Phase 3 trial of CT-L03 in type 2 diabetes mellitus (T2DM), sponsored by Celltrion. Started Aug 2024; status: completed.
02
Drugs
CT-L03
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06571591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571591.